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INTRODUCTION

Despite decades of research and multiple clinical trials, complete
vaccine control of dengue virus (DENV), a member of the flavivirus
family, has remained elusive (1, 2). About 25% of the ~400 million
annual DENV infections worldwide result in dengue fever or dengue
hemorrhagic fever, which could be avoided with effective vaccine
control of DENV (2, 3). Dengue is caused by four closely related but
antigenically distinct virus serotypes. Individuals undergoing a primary
infection with one of the DENV serotypes develop serotype-specific
protective immunity but remain susceptible to secondary infections
with one of the other serotypes (2). As DENV serotypes cocirculate
in most tropical regions of the world, secondary infections are common (3, 4). These secondary DENV infections increase the risk of
developing severe and potentially fatal disease symptoms, such as
dengue hemorrhagic fever and shock syndromes (2, 5).
A supported hypothesis for the cause of these severe dengue
clinical manifestations is through increased viral burden associated
with antibody-dependent enhancement (ADE). Non-neutralizing,
serotype cross-reactive antibodies elicited from a primary DENV
infection can bind to the secondary DENV serotype and allow for
enhanced infection through Fc receptor–mediated endocytosis of
1
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the virus (2, 5, 6). As immunity to only one serotype has the potential
to enhance infections caused by other serotypes, leading DENV
vaccines are based on tetravalent live-attenuated virus formulations
to induce protective responses to all four serotypes. However, these
vaccines have notable safety and efficacy concerns, in part, because of
uneven replication efficiency of each viral vaccine component. The
unbalanced replication causes variable vaccine efficacy between serotypes and, therefore, priming immune responses that increase the
severity of wild-type (WT) DENV infections (7, 8). These observations highlight the need for alternative vaccination strategies to protect all groups at risk of infection.
The DENV lipid envelope contains 180 copies of the envelope
glycoprotein (E), which covers the surface of the virus particle
(9, 10). On the mature infectious virus particle, E is arranged in a
herringbone pattern as antiparallel homodimers that pack laterally
into a lipid raft containing three dimers (9, 10). The E protein
monomer contains three predominantly  sheet domains (DI, DII,
and DIII) connected to a transmembrane domain by an amphipathic
helix (Fig. 1A) (9). As DENV enters the cell, the E protein undergoes a pH-induced conformational change from a dimeric to a trimeric form that triggers fusion of viral and endosomal membranes
required for releasing the viral genome into the cytoplasm of the cell
(9–12). This critical conformational change provides selective pressure during viral evolution that favors E protein sequences that are
adept at transitioning between different structures and are not overly
stable in a single conformation such as the prefusion dimer (10).
The DENV E protein is the primary target of neutralizing antibodies, which has led to a large body of work to assess the immunogenicity and efficacy of this protein as a subunit vaccine (10, 13, 14).
Recent studies have shown that human antibodies that target quaternary epitopes that span across both chains of the E dimer are
potently neutralizing and provide protection against DENV infection (15–21). However, E protein–based subunit vaccines have had
1 of 18
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Dengue virus (DENV) is a worldwide health burden, and a safe vaccine is needed. Neutralizing antibodies bind
to quaternary epitopes on DENV envelope (E) protein homodimers. However, recombinantly expressed soluble
E proteins are monomers under vaccination conditions and do not present these quaternary epitopes, partly explaining their limited success as vaccine antigens. Using molecular modeling, we found DENV2 E protein mutations
that induce dimerization at low concentrations (<100 pM) and enhance production yield by more than 50-fold.
Cross-dimer epitope antibodies bind to the stabilized dimers, and a crystal structure resembles the wild-type (WT)
E protein bound to a dimer epitope antibody. Mice immunized with the stabilized dimers developed antibodies
that bind to E dimers and not monomers and elicited higher levels of DENV2-neutralizing antibodies compared to
mice immunized with WT E antigen. Our findings demonstrate the feasibility of using structure-based design to
produce subunit vaccines for dengue and other flaviviruses.
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Fig. 1. DENV2 sE dimer- and monomer-stabilizing mutations identified using Rosetta computational design. (A) Sequence and structural organization of the
DENV2 sE dimer (PDB 1OAN). (B) Overview of the computational design pipeline. (C) The cluster mutation protocol was used to identify small sets of stabilizing mutations
adjacent in three-dimensional space. Each simulation centered on a seed residue (dark blue) that, along with residues within 7 Å (light blue), was allowed to mutate.
Residues out to 10 Å from the seed residue (tan) were allowed to adopt alternative conformations to accommodate the mutations. (D and E) Seed residues for the cluster
mutation protocol were chosen from four regions in the protein: residues at the dimer interface (IntFc), residues forming histidine-cation interactions (HCat), underpacked
regions (UndPk), and surface-exposed hydrophobic amino acids (SHP). The underpacked regions [shown as gray spheres in (E)] were identified using the RosettaHoles
protocol (30). (F) In addition to the cluster mutation protocol, in silico site-saturation mutagenesis was used to scan through the protein to identify favorable point mutations.
Point mutations predicted to be favorable for different regions of the protein (entire domains, domain interfaces, or the dimer interface) were then tested in combination
using the PM_Comb protocol. BB, backbone.
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limited success in clinical trials (14). The poor performance of
DENV E protein–based subunit vaccines may be partially attributed
to not presenting the important quaternary epitopes responsible for
eliciting neutralizing and protective antibodies. Recombinantly
expressed soluble DENV2 E proteins (sE) exhibit a dynamic equilibrium between monomer and dimer with a dissociation constant
(Kd) of 12 M at 37°C (9, 14, 22–24) and, thus, are predominately in the
monomeric state at the typical concentrations used for vaccination.
Here, we use molecular modeling to design variants of DENV2
sE that are dimeric at physiological conditions and present quaternary epitopes that are recognized by human antibodies that potently
neutralize DENV2. Our work makes use of new methods developed
for computational protein design in the software package Rosetta
(25). Similar strategies have been used recently to stabilize and present
selected epitopes from respiratory syncytial virus (RSV) and HIV
(26–29). Our work demonstrates how structure-based design can
be used to focus the immune response toward critical features on
the surface of pathogenic flaviviruses.

Molecular modeling simulations to design DENV2
sE–stabilized dimers
To stabilize the DENV2 sE dimer, we used the molecular modeling
program Rosetta to identify amino acid mutations that either strengthen
contacts across the dimer interface or stabilize the monomer in the
conformation that it adopts when forming a dimer (Fig. 1B). Starting from crystal structures of the DENV2 sE dimer, a large set of
Rosetta FastDesign (25) simulations (>7000 per structure, ~28,000
total) was performed in which each simulation focused on optimizing a different region of the protein or dimer interface. The goal was
to identify small sets of localized mutations (one to four mutations)
that could be tested experimentally and then later combined to create
larger gains in stability. The design protocol (cluster_mut) incorporated a design sphere in which all residues within 7 Å of a seed residue
(including the seed residue) were allowed to mutate to any amino
acid except cysteine (Fig. 1C). Surrounding the design sphere was a
3-Å layer in which side chains could adopt new conformations during
the simulation, but the amino acid identities were fixed. Outside of
the two spheres, the side chains were fixed. In all design runs, mutations were not allowed at residues known to interact with potently
neutralizing antibodies (Fig. 1B).
To focus the cluster_mut design simulations, we identified seed
residues in regions within the DENV2 sE protein that we hypothesized to contribute to protein dimer and/or monomer instability
(Fig. 1, D and E). Four sets of simulations were performed: The “IntFc”
simulations incorporated seed residues directly at the dimer interface, the “UndPk” simulations focused on buried regions in the protein
identified as being underpacked, the “HisCat” simulations replaced
interactions between histidines and cationic amino acids (arginine
and lysine), and the “SHP” design runs focused on removing hydrophobic patches on the surface of the protein. Underpacked regions
were identified using the RosettaHoles protocol (30), which detects
buried regions in a protein where amino acids do not closely interact. Large underpacked regions were identified in the highly flexible
“hinge” regions that connect DI with DII and DIII. During the viral
life cycle, the E protein adopts several alternative structures that involve large conformational changes in the hinges. Thus, it is likely
that these regions of the protein are not optimized to maintain a
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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Mammalian surface display screening of sE variants
for quaternary antibody epitope presentation
To screen for sE variants that form a dimer at temperatures relevant
to vaccination, we expressed the Rosetta-designed variants on the
surface of EXPI293F cells and used flow cytometry to measure binding
between the variants and antibodies that target quaternary epitopes
on DENV2. To enable cell surface display, we fused the transmembrane and cytoplasmic domains of the major histocompatibility
complex I (MHC-I)  chain to the C terminus of the E protein
ectodomain (residues 1 to 394) and used an N-terminal human
serum albumin signal peptide to direct the protein to the cell surface
(32). A cMyc tag was also included in the linker between E protein
and the MHC-I transmembrane domain to measure the amount of
protein expressed on the cell surface. Epitope presentation was
assessed by measuring the binding of DENV2 type-specific (TS)
antibody (2D22) and cross-reactive (CR) neutralizing quaternary
epitope antibodies (EDE1 C8 or EDE1 C10) to cells displaying
membrane-anchored sE protein at 23° or 40°C [peridinin-chlorophyll-
protein (PerCP)–positive fluorescence; Fig. 2 and fig. S1]. We also
probed for the binding of single-domain epitope antibodies including
3H5 (DIII) and 1C19 (DII/bc loop) as a readout for proper folding
of the variants (Fig. 2B and fig. S1). At 23°C, most of the design
variants and WT sE were efficiently recognized by dimer-specific
monoclonal antibodies 2D22 and EDE1 C8, indicating that, at 23°C,
most variants were displayed as properly assembled dimers (fig. S1).
Next, we analyzed the integrity of quaternary epitopes at 40°C. In
contrast to the 23°C screen, 2D22 and EDE1 C10 bound poorly to
WT sE (Fig. 2C and fig. S1). Of 34 design variants tested, 23 bound
more 2D22 and EDE1 C10 than WT sE, and 8 design variants
(HCat3, IntFc2, IntFc8, UndPk6, PM2, PM4, SHP1, and SHP2) had a
threefold or higher binding, suggesting that these variants were forming more stable dimers compared to WT sE at >37°C (Fig. 2, B and D,
and fig. S1).
3 of 18
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RESULTS

dimer conformation. We also focused our simulations on histidine-
cation interactions as these residues are “pH-sensing” residues that
mediate the E conformational change from prefusion dimer to
postfusion trimer but are unlikely to be optimal for high dimer
stability (9, 31).
We also used Rosetta to scan through the protein and calculate
the change in protein energy for all possible point mutations (Fig. 1F).
The most favorable point mutations were combined for further computational testing (“PM_comb”), and favorable combinations were
selected for experimental testing.
After performing the various design simulations, from the pool
of designs that had improved Rosetta energy scores compared to WT,
eight designs were selected from each of the protocols: PM_Comb
(PM), UndPk (underpacked), HCat (histidine-cation) and IntFc
(interface), and two designs from the SHP (surface hydrophobic to
polar) simulations for experimental studies. Recent studies have
also demonstrated that a covalently cross-linked sE protein dimer
can be formed by introducing disulfides across the dimer interface (32, 33). We included two of these variants, Cm1 (A259C)
and Cm2 (L107C and A313C), in our studies. We also selected
two mutants (Mnmer1 and Mnmer2) from the point mutant scan
that were predicted to destabilize the dimer with the goal of creating sE protein that would remain a monomer even at higher
concentrations and low temperature for use as controls in our
experiments.
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Fig. 2. Screening of DENV2 sE designs for binding to quaternary epitope antibodies with mammalian cell surface display. A) DENV2 sE (blue/light blue) proteins
were displayed on the surface of EXPI293F cells by genetically fusing their C termini to the MHC I cytoplasmic and transmembrane (TM) domains (green) via a glycine-serine
(GS) linker. A cMyc epitope tag (brown) was inserted for detection of successful surface display by anti-cMyc antibody binding (orange). Quaternary epitope presentation
by the DENV2 sE variants was assessed by testing for binding of representative quaternary epitope antibodies (purple). CPD, cytoplasmic domain. (B) Flow cytometric
analysis of monomer epitope antibody 3H5 (gray) and cross-reactive EDE1 C10 (QuatCR; blue) and type-specific 2D22 (QuatTS; red) quaternary epitope antibody binding
to surface-displayed DENV2 sE WT, DENV2 sE variants (Cm2, IntFc2, IntFc8, and UndPk6), and a membrane anchor–negative control (MHC ctrl). The geometric mean
fluorescence ratios of sE variant to sE WT surface displayed cells after antibody immunostaining are plotted. (C and D) Flow cytometry data for cells displaying DENV2 sE
WT (C) or DENV2 sE UndPk6 (D) at 40°C labeled with an anti-cMyc antibody (x axis) and the EDE1 C10 quaternary epitope antibody (y axis).

Design variants increase DENV2 sE dimer stability
and expression yields
On the basis of the mammalian cell surface antibody epitope display
results, we selected 22 design variants, Mnmer2, and Cm1 and Cm2
for further characterization as soluble secreted proteins. The sE variants
were expressed in EXPI293F cells and purified using His-tag affinity
chromatography (fig. S2). Sixteen of the 22 Rosetta design variants
had expression yield levels comparable to or greater than WT sE
(Fig. 3A and table S1). Three variants in particular showed a large
increase in expression yield, PM4 (10-fold), IntFc8 (19.1-fold), and
UndPk6 (22.5-fold). In general, the Rosetta variants that had increased
quaternary antibody epitope display at 40°C on the mammalian cell
surface also had increased expression yields as a soluble protein.
The disulfide variants, Cm1 and Cm2, expressed at much lower
levels than WT sE.
Next, we measured dimer Kds and thermal unfolding temperatures of the sE variants using nanoscale differential scanning fluorimetry (nanoDSF). In a previous study, we observed two transitions
in the DENV2 sE WT thermal unfolding curve. Using various
methods, we showed that the midpoint of the first transition, which
we refer to as Tm1, reports on the dissociation of the sE dimer, and
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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the second transition, Tm2, corresponds to unfolding of the sE monomer (Fig. 3B). Tm1 is dependent on the concentration of the protein,
and by performing the nanoDSF experiment at various concentrations, it is possible to determine the Kd for the monomer-dimer
equilibrium at 37°C. For DENV2 sE WT at 4 M, Tm1 is 34.2°C and
Tm2 is 51.0°C (Fig. 3, C and D, and table S1) (24). Aside from Mnmer2
and the disulfide variants, Tm1 and Tm2, transitions were observed
for all Rosetta variants (table S1). No Tm1 transitions were observed
for Mnmer2 and the disulfide dimers, consistent with them being
constitutively monomeric or covalently linked dimers, respectively.
Four design variants—IntFc2, IntFc8, UndPk6, and PM4—
produced particularly large increases in Tm1 and/or Tm2 (Fig. 3, C
and D, and table S1). IntFc2 (A259W/T262R) creates two new pi-
cation interactions across the underside (i.e., the side of the dimer
facing the membrane) of the B helix central dimer interface and
raised Tm1 by 10.5°C. IntFc8 (G106D) is located in the fusion loop
(FL) and introduces new electrostatic interactions at the interchain
interface between DII and DIII and raises Tm1 by 8.1°C. The variant
UndPk6 (F279W/T280P) is particularly interesting as it stabilizes
the dimer and monomer simultaneously (+8.7°C Tm1 and +5.9°C
Tm2) (table S1). These mutations are located in the hinge between
4 of 18
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Fig. 3. DENV2 sE designs have higher production yields and thermostability. (A) Protein yields following expression in EXPI293F cells and purification with metal
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DI and DII and are predicted to stabilize the hinge in the conformation the E protein adopts when forming the dimer. As prolines are
particularly effective at locking protein loops in specific conformations, we tested the point mutation T280P (UndPk6.1) alone and
observed increases in Tm1 of 6.4°C and Tm2 of 2.6°C, indicating that
T280P accounts for much of the increased dimer stability from UndPk6 (table S1). Last, the PM4 mutations (S29K, T33V, and A35M)
are located in the core of domain I and do not interact at the dimer
interface or contribute to interactions in the E protein hinges. Consistent with this observation, the PM4 mutations markedly raised
Tm2 by +11.4°C but had no effect on Tm1 (Fig. 3, C and D, and table
S1). This result indicates that domain I is a key factor in the low
overall thermostability of the sE monomer.
We measured the homodimer affinity of the most stable dimer
variants by performing nanoDSF at protein concentrations ranging
from 2 to 16 M, allowing us to use a van’t Hoff analysis to estimate
the equilibrium Kd at 37°C (24). For all variants and WT sE, we observed increasing Tm1 values with increasing protein concentrations.
WT DENV2 sE had a Kd of 12.9 M, and IntFc2 had a Kd of 23 nM
at 37°C, demonstrating a >500-fold increase in the variant’s dimer
affinity over WT (table S1). Similarly, for IntFc8 and UndPk6, we
measured Kd values of 219 nM (~17-fold increase) and 238 nM
(~18.5-fold increase), respectively (table S1). To further validate the
design variants that were forming dimers at 37°C, we used size exclusion chromatography coupled with multiangle light scattering
(SEC-MALS) to measure the oligomeric state of these variants at
37°C. Unlike the sE WT that elutes predominantly as a monomer at
37°C (Fig. 4A), IntFc2, IntFc8, and UndPk6 all had MALS-measured
molecular masses (MMs) consistent with dimer formation (Fig. 4B).
Mnmer2 eluted as two peaks, both with measured MM nearly identical to the theoretical monomer weight, indicating that the protein is a
constitutive monomer, and it may be adopting two alternative
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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conformations (33). A similar SEC-MALS profile has been previously observed for WT DENV2 sE.
Combining stabilizing mutations further increases DENV2 sE
dimer stability and expression yields
To determine whether combinations of Rosetta-designed mutations
can raise dimer stability even further, we tested 28 stable combination (SC) variants built from our most stabilizing designs: IntFc2,
IntFc8, UndPk6, PM4, and HCat3. The SC variants were expressed,
purified, and tested for dimer and monomer stability using nanoDSF
thermal melts. All SC variants had improved expression yields, with
some increasing yield >50-fold (variant) compared to WT (table S1).
In general, increases in Tm1 and Tm2 were additive, and many of the
SC variants exhibited large increases in Tm1 and Tm2. Variant SC.14
containing just four mutations from two of the best stabilizing dimer
mutation sets, IntFc2 and UndPk6, had a Tm1 of 50.2°C (+16.1°C
relative to WT) and a Kd of 12 nM at 37°C (table S1). Variant SC.10,
which builds on SC.14 with a single additional mutation G106D
(IntFc8), further raised Tm1 to 53.9°C and lowered the Kd to less
than 100 pM at 37°C (table S1). The exceptional stability of the SC.10
dimer is likely due to simultaneously stabilizing the central dimer
interface (IntFc2), the hinge (UndPk6), and the FL dimer interface
(IntFc8), all critical regions that regulate dimer stability. Consistent
with the nanoDSF analysis, both SC.14 and SC.10 eluted as a single
peak upon analysis with SEC-MALS at 37°C with MM of 99.5 and
102.2 kDa, respectively, similar to the disulfide stabilized sE dimer,
Cm1 (Fig. 4, C and D).
DENV2 sE SC.10 adopts the same dimer conformation
as the EDE1 C8 bound sE dimer
To compare SC.10 and WT sE structures and to validate the accuracy
of the Rosetta design models, we determined the crystal structure of
5 of 18

Downloaded from https://www.science.org at University of the Pacific on January 10, 2022

Expression

SCIENCE ADVANCES | RESEARCH ARTICLE

WT23°C
WT37°C
M237°C

100

0.6
0.4
0.2
12

14

16

10
20

18

Volume (ml)

Cm1

0.6

100

0.4

0.6

12

14

16

18

10
20

100

0.4
0.2
0.0
10

12

14

16

18

10
20

Volume (ml)
Expected
molar mass (kDa)

Measured
molar mass (kDa)

Dimer
90.2

Monomer
45.1

Peak 1

Peak 2

91.0 ± 0.7

57.5 ± 3.7

WT37°C
Mnmer2 (M2) 23°C

90.2

45.1

61.6 ± 1.6

90.8

45.4

45.4 ± 5.9

WT37°C
IntFc2 (I2)37°C
IntFc8 (I8)37°C
UndPk6 (U6)37°C
PM4 (P4)37°C

90.2
91.0
90.8
90.8
91.0

45.1
45.5
45.4
45.4
45.5

61.6
92.4
88.4
87.2
60.1

SC.1437°C

91.2

45.6

99.5 ± 0.9

SC.1037°C
Cm137°C

91.6

45.8

102.2 ± 1.3

90.2

45.1

100.7 ± 1.9

WT23°C

±
±
±
±
±

44.1 ± 2.6

1.6
1.6
1.6
1.5
2.6

Volume (ml)
Fig. 4. SEC-MALS confirms that DENV2 sE designs form dimers at 37°C. (A to C) SEC-MALS experiments were performed at room temperature and 37°C. Protein concentrations were between 30 and 55 M. The molar mass as measured by light scattering is shown by the dots (values indicated by the right y axis of each plot). Abbreviations used for the variants in (A) and (B) are the following: WT, M2 (Mnmer2), I2 (IntFc2), I8 (IntFc8), U6 (UndPk6), and P4 (PM4). (D) A comparison of the expected and
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SC.10 at 3.42 Å using molecular replacement (MR) (table S2). Despite growing the crystal at pH 4.4, SC.10 retained the prefusion
DENV2 sE dimer conformation (Fig. 5A). This contrasts with the
WT DENV1 sE protein, which crystallized as the postfusion trimer
at pH 4.5 (34). The fact that SC.10 remains a dimer at low pH is
consistent with the increased dimer stability of SC.10. We structurally aligned the SC.10 dimer structure to the previously solved crystal structures of WT DENV2 sE protein. The closest match was to
the sE protein cocrystallized with human monoclonal antibody
EDE1 C8 [Protein Data Bank (PDB) 4UTA], a DENV broadly neutralizing quaternary epitope antibody (16), with a C root mean
square deviation (RMSD) of 1.7 Å (Fig. 5B). The C RMSD with the
unliganded DENV2 WT sE protein crystallized at pH 9.0 (PDB
1OAN) is 3.5 Å.
Further comparison of the SC.10 structure with the WT sE crystal structure showed that the small structural differences were due
to changes in the DI/DII hinge angle (Fig. 5B). Analysis of multiple
DENV sE crystal structures and cryo–electron microscopy (cryoEM) structures of the mature virion has revealed that the E protein
DI/DII hinge angle is variable, consistent with the intrinsic dynamics and multiple conformations that the E protein can adopt
(9, 12, 22, 23, 35). In the cryo-EM structures of the virion, the DI/
DII hinge bends, allowing the E dimer to match the curvature of the
virion, while in previously determined crystal structures of the sE
dimer, the dimer crystallizes in a more straight or flat conformation
(35). The SC.10 crystal structure follows this pattern and has a DI/
DII hinge angle that supports a conformation that is flatter than
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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what is observed on the virion. However, these changes do not appear to have a large influence on the binding of potently neutralizing EDE1 human monoclonal antibodies because the WT DENV2
sE protein crystallized with EDE1 antibodies adopts a conformation
that is similar to the structure we observed for SC.10 (16, 36).
Clear electron density was observed for all sets of mutations
(IntFc2, IntFc8, and UndPk6) in the SC.10 crystal structure (fig. S3A).
The two UndPk6 mutations, F279W and T280P, are in the kl loop
of the DI/DII hinge. F279W fills an underpacked region in the hinge
as predicted (Fig. 5A). T280P is at the base of the kl loop, and in the
SC.10 structure, the backbone at residue 280 is shifted to create a
new backbone side chain hydrogen bond between the P280 backbone carbonyl and the T189 side chain hydroxyl in an adjacent
loop. In addition to the structural rigidity that prolines can provide,
the new hydrogen bond may be helping to stabilize the sE dimer
(37, 38). As predicted by the Rosetta model, the two mutations in
IntFc2, T262R and A259W, lead to canonical pi-cation interactions
across the central dimer interface between R262 on one chain and
W259 on the other chain (Fig. 5A). IntFc8 contains a single mutation in the FL, G106D, which we predicted to form a new salt bridge
with K310 across the dimer interface. Instead, in the SC.10 structure,
D106 forms an intradomain hydrogen bond with Q77, and alternative rotamers are observed for K310 and W101 (Fig. 5A). These
changes may be a consequence of low pH as in the SC.10 structure
the ij loop, and the N termini have conformational changes near the
FL that match more closely to the DENV sE structures also solved at
low pH (fig. S3B). In addition, the low pH makes protonation of
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D106 more likely, which could favor hydrogen bonding to Q77 over
formation of a salt bridge with K101 (39). Thus, from our low pH
structure, it is not clear how G106D is enhancing dimer stability.
DENV2 sE SC.10 and SC.14 bind to quaternary epitope
antibodies at 37°C and have reduced affinity for
FL antibodies
With the crystal structure confirming the dimeric structure of
SC.10, we tested the binding of DENV2 antibodies to SC.10 and
SC.14. Enzyme-linked immunosorbent assay (ELISA) experiments
were performed at 37°C by incubating a panel of DENV2 TS and
DENV CR domain, and quaternary epitope–neutralizing antibodies
with DENV2 sE variants (Mnmer2, WT, Cm1, SC.14, and SC.10)
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084

15 October 2021

were immobilized on a nickel-coated ELISA plate (Fig. 6A). The sE
variants were loaded onto the plates by incubating 45 nM sE protein
with the plate for 1 hour at 37°C. At this E protein concentration
and temperature (which is representative of vaccination conditions),
the WT sE protein is primarily monomeric, while the stabilized sE
variants are dimeric. Binding of DIII-specific (3H5) (40), DI-specific
(3F9) (17), and DII-specific (1C19) (41) antibodies was observed
for all five DENV2 sE proteins (Fig. 6, B to F). Unlike the domain-
specific antibodies, the quaternary epitope antibodies, EDE2 A11,
2D22, and EDE1 C8 (17) (15, 16) only bound to Cm1, SC.14, and
SC.10 (Fig. 6, D to F). We also tested binding of the FL epitope (FLE)
antibodies, 4G2 (42) and 1M7 (41), to each of the DENV2 sE proteins. The FLE antibodies are poorly neutralizing and cross-reactive
7 of 18

Downloaded from https://www.science.org at University of the Pacific on January 10, 2022

DENV2 sE SC.10
DENV2 sE + EDE1 C8 (4UTA)

IntFc8

SCIENCE ADVANCES | RESEARCH ARTICLE

B

Absorbance (405 nm)

1.0

0.5

0.0

E

1.0

0.5

0.4

0.1

0

500

1000

1500

0.2
0.1
0

0

500

−0.1

K

Cm1 binding to C10

1000

1500

Response (nm)

0.1

0

500

1000

1500

Time (s)

50 nM
25 nM
12.5 nM
6.25 nM

0.3
0.2

0
−0.1

1F
4

3H
5
2D
2
2
ED
E1
C8
ED
E2
A1
1

7
1C
19

4G
2

4
1F

A1
1

ED

E2

22

C8

E1

5
3H

2D

7

19
1C

2

0

500

0

500

1000

1000

1500

2000

2000

1500

Time (s)

Steady-state binding constants Kd (nM)
Ab

4G2

3H5

2D22

EDE1 C8

EDE1 C10

WT

11.0 ± 0.9

8.6 ± 0.8

480 ± 60

300 ± 41

>1000

Cm1

130.0 ± 4.7 7.4 ± 1.0

6.3 ± 0.7

32.0 ± 4.2

22.0 ± 3.6

11.0 ± 1.2

480 ± 23

370 ± 23

ND

sE

Mnmer2 9.7 ± 0.7

0.1

2000

0.1

L

Mnmer2 binding to C10
[EDE1 C10]

0.2

0.2

−0.1

0.4

0.3

0.3

0

2000

Time (s)

0.5

0.4

1M

3F
9
9

ED

0.3

2000

Time (s)

0.5

0.4

Response (nm)

Response (nm)

0.2

−0.1

Response (nm)

SC.14 binding to C10
0.5

0.4

0.3

−0.1

3F

4
1F

A1
1

ED

I

SC.10 binding to C10

0.5

0.5

E2

22

C8

5

ED

E1

2D

7

19

3H

1C

2

1M

9
3F

H

WT binding to C10

0.5

4G

4
1F

C8

A1
1

E1

E2

ED

ED

5

22

3H

2D

7

19
1C

2

1M

9
3F

4G

G

1.0

0.0

0.0

0.0

Response (nm)

Absorbance (405 nm)

Absorbance (405 nm)

0.5

1.5

SC.10

>1000

7.2 ± 0.2

15.0 ± 0.3

42.0 ± 3.7

57.0 ± 5.4

SC.14

21.0 ± 1.7

8.2 ± 0.6

5.2 ± 0.1

31.0 ± 1.7

31.0 ± 1.7

Time (s)

Fig. 6. Epitope presentation of DENV2 sE designs assessed by binding of monomer and quaternary epitope antibodies. ELISA antibody binding analysis at 37°C of
DENV E monomer and quaternary epitope antibodies (A) with the indicated DENV2 sE variants (B to F). sE protein (100 ng) at 45 nM was immobilized on a nickel-coated
ELISA plate and incubated with 100 ng at 0.2 ng/ml of each antibody. The binding signal for the antibodies that bind quaternary epitopes (2D22, EDE1 C8, and EDE2 A11)
are shown in black. Binding measurements were performed in triplicate, with error bars representing the mean 405-nm signal ± SD of the mean. BLI sensorgrams showing
the binding of EDE1 C10 to DENV2 sE variants at 37°C (G to K). sE (10 nM) was loaded on Ni-NTA sensors and analyzed across different concentrations of EDE1 C10
(6.25 to 50 nM). Steady-state binding affinities were calculated from BLI binding responses between DENV2 sE variants and different anti-E antibodies (L). “ND,” not determined due to the inability to fit. Errors to the fit are indicated for each measurement.
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084

15 October 2021

8 of 18

Downloaded from https://www.science.org at University of the Pacific on January 10, 2022

Absorbance (405 nm)

1.0

0

SC.10

1.5

1.5

J

F

SC.14

4G

Cm1

0.5

0.0
3F
9

EDI/II hinge

1.0

1F
4

EDI
EDII FL
EDII FL
EDII BC loop
EDIII lateral ridge
Quaternary/dimer
Quaternary/dimer
Quaternary/dimer
Quaternary/dimer

3H
5
2D
ED 22
E1
C8
ED
E2
A1
1

Epitope

DV2 TS
CR
CR
CR
DV2 TS
DV2 TS
CR
CR
CR
DV1 TS

1M
7
1C
19

TS/CR

Human
Mouse
Human
Human
Mouse
Human
Human
Human
Human
Human

0

WT
1.5

4G
2

Species

3F9
4G2
1M7
1C19
3H5
2D22
EDE1 C8
EDE1 C10
EDE2 A11
1F4 (control)

Absorbance (405 nm)

Antibody

D

C

Mnmer2
1.5

1M

A

SCIENCE ADVANCES | RESEARCH ARTICLE

DENV2 sE SC.14 and SC.10 elicit DENV2 E dimer–specific
antibodies in mice
Next, we tested whether mice immunized with stable dimers developed antibodies to epitopes displayed on dimers but not on monomers. Mice were primed and boosted with WT sE, Mnmer2, SC.14,
and SC.10, without the addition of adjuvant to evaluate the impact
of antigen structure on antibody specificity. All antigens stimulated
DENV2-binding antibodies (fig. S5). We performed antigen-specific
antibody depletions to determine whether mice immunized with
stabilized dimers developed dimer-specific antibodies. The mouse
immune sera were incubated with magnetic beads coated with
monomers (Mnmer2) or dimers (SC.14) to deplete specific antibody populations and then tested for binding to monomers, dimers,
and DENV2 virions (Fig. 7A). Mice immunized with WT sE or
Mnmer2 developed antibodies that were equally effectively depleted
using monomers or dimers (Fig. 7, B and C). This result indicates
that animals immunized with these antigens mainly develop antibodies that target single-domain epitopes that are present on both
monomers and dimers. Animals immunized with stable dimers
(SC.14 and SC.10) developed DENV2-binding antibodies that were
efficiently depleted with the dimer (Fig. 7, B and C). Dimer-immune
sera consisted of antibody populations that were sensitive and
refractory, respectively, to depletion using monomers (Fig. 7, B and C).
These results establish that immunization with stable dimers induced
antibodies to shared epitopes between monomers and dimers and a
new population of antibodies that only bound to the dimer.
The DENV binding signals for the monomer-depleted SC.10
and SC.14 immune sera at the lowest dilutions were higher than the
control-depleted sera (Fig. 7B). This unexpected result can be explained by assuming that the antigens induce a mixture of abundant
low-affinity (Abslow) and less-abundant high-affinity (Abshigh) antibodies that are either directed to share epitopes on monomers and
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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dimers or to dimer-specific epitopes. In undepleted or control-depleted
serum samples, the abundant Abslow will outcompete the minor
population of Abshigh during initial binding to virus. However, the
Abslow are more prone to be washed off during the subsequent wash
steps, resulting in lower binding signals. The monomer depletion
will selectively remove the Abslow and promote the binding of dimer-
specific Abshigh. The Abshigh remain bound during the wash steps,
leading to higher binding signal at high concentrations of monomer-
depleted sera. Similar increases in ELISA binding signal following
depletion have been observed when examining sera from mice immunized with antigens from tick-borne encephalitis, and in this
case, the explanation also involved a mixed population of higherand lower-affinity antibodies (46). To further support our hypothesis,
we created a mathematical binding model that simulates lower-
affinity (Kd = 10 nM) and higher-affinity (Kd = 1 nM) antibody populations binding to virus and then unbinding during subsequent
wash and incubation steps. Both populations of antibodies were
given the same association rate constants typically observed with
antibody-antigen binding, but the higher-affinity antibody population was assigned an off-rate that was 10-fold slower (fig. S6, A
to C). When incorporating association times (TA) and dissociation
times (TD) that match the incubation times and wash times used in
the ELISA protocol into the model, we were able to reproduce the
trends observed in the DENV2 ELISA (fig. S6, B and C). This suggests that the E dimer–specific antibodies elicited by SC.14 and
SC.10, although lower in abundance, may be higher-affinity antibodies and compete for binding to similar regions on the virus as
the more abundant, Abslow whose epitopes shared between monomers and dimers.
To characterize the levels of DENV2-neutralizing antibodies
induced by these antigens, we repeated the immunization studies with
WT sE, Mnmer2, and SC.10 antigens formulated with Alhydrogel
as an adjuvant. Groups of six mice were primed and boosted 3 weeks
later. The animals were bled 5 weeks after the boost (study week 8)
to measure levels of DENV2-binding and DENV2-neutralizing
antibodies. As anticipated, in the presence of adjuvant, the antigens
stimulated higher levels of DENV2-binding antibodies compared to
animals immunized with no adjuvant (Fig. 8 and figs. S5 and S8).
With adjuvant, mice that received the SC.10 stable dimer variant
developed significantly (P = 0.03) higher levels of DENV2-neutralizing
antibodies compared to animals immunized with WT sE or Mnmer2
antigens (Fig. 8). In a second immunogenicity study, groups of five
mice were immunized with WT sE and the SC.14 stable dimer variant
formulated with Alhydrogel as an adjuvant. The group that received
the SC.14 dimer variant had a trend (P = 0.08) of more DENV2-
neutralizing antibody compared to the group that was immunized
with the WT sE antigens (fig. S8).
DISCUSSION

During the natural life cycle of flaviviruses, the E protein undergoes
large conformational changes and interacts with a variety of
macromolecular partners. These diverse functional requirements
constrain the evolution of E protein sequences, and, therefore,
native E protein sequences are unlikely to be optimized for any one
conformation or interaction. One potential advantage of subunit
vaccines compared to live attenuated viruses is that viability is no
longer a constraint that restricts the sequence space that can be
utilized. Instead, the focus can be on engineering molecules that are
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with other DENV serotypes, and antibodies of this type have been
implicated in ADE during infection (43). Both 4G2 and 1M7 bound
well to Mnmer2 and WT (Fig. 6, B and C) but had reduced binding
to Cm1 and SC.14 (Fig. 6, D and E), consistent with the previous
observation that sE dimer stabilization reduces FLE exposure (33, 44).
Little or no binding was observed to SC.10 (Fig. 6F). Mutations at
G106 are known to eliminate 4G2 binding (SC.10 contains G106D)
(45), but it has been reported that 1M7 is not sensitive to mutations
at G106 (41). This indicates that the reduced binding of 1M7 is due
to increased stabilization of the dimer.
To further probe the binding properties of the stabilized E dimers, we performed biolayer interferometry (BLI) experiments at
37°C. DENV2 sE variants (Mnmer2, WT, Cm1, SC.14, and SC.10) were
immobilized on nickel nitrilotriacetic acid (Ni-NTA) biosensors and
tested for binding with a panel of DENV2 antibodies (Fig. 6, G to L,
and fig. S4). Consistent with the ELISA experiments, the dimer-
specific antibodies (2D22, EDE1 C8, and EDE1 C10) bound more
tightly to the stabilized E dimers SC.10, SC.14, and Cm1 (Kd < 60 nM)
than WT E and Mnmer2 (Kd > 300 nM) (Fig. 6L). As expected,
all the E variants bound tightly to the domain III–specific antibody
3H5. As observed in the ELISA experiments, SC.10, which contains
the mutation G106D, did not bind to the FLE antibody, 4G2.
Together, the ELISA and BLI experiments demonstrate that the
stabilized E dimers, SC.10 and SC.14, present quaternary structure
epitopes recognized by human antibodies that potently neutralize DENV.
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in mouse immune sera after control depletion (black) or removal of sE monomer (blue)– or dimer (red)–binding antibodies. The graphs depict the absorbance ± SD of the
mean for all mice (n = 5) in each group. OD405, optical density at 405 nm. (C) To compare levels of E dimer–specific antibodies in mice immunized with different antigens,
sera were depleted of sE monomer- or dimer-binding antibodies and tested by ELISA for DENV2-, sE monomer (Mnmer2)–, and sE dimer (SC.14)–binding antibodies. The
graphs depict the ratio of the end point dilution (EPD) titer after depleting monomer-binding antibodies divided by the EPD titer after dimer depletion. A ratio > 1 is
indicative of antibodies binding to epitopes displayed on the dimer only.
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Fig. 8. DENV2-neutralizing antibody levels in mice immunized with WT sE and stabilized dimer variants in the presence of Alhydrogel. Groups of six C57BL/6J
mice were primed and boosted at 3 weeks with 5 g of WT sE (A), Mnmer2 (M2) (B), or the SC.10 stable dimer (C) with 500 g of Alhydrogel. All the mice were bled 5 weeks
after the boost for antibody testing. To measure virus-neutralizing antibodies, each serum sample was serially diluted and tested in duplicate in a DENV2 focus reduction
neutralization assay (A to C). The 50% DENV2-neutralizing antibody titers were significantly greater in mice immunized with the SC.10 sE antigen compared to titers in
animals immunized with the WT sE antigen (D). The means of the antibody responses induced by the different antigens were compared by an unpaired t test. ns, not
significant.

optimized to elicit a specific immune response. In our study, we
demonstrate that structure-based protein design can be used to
identify small numbers of amino acid mutations that markedly stabilize the E protein dimer and raise secretion yields more than
50-fold. Unlike the WT DENV2 sE protein, our design variants
form dimers at 37°C and present quaternary epitopes recognized by
human potently neutralizing antibodies. Our results highlight the
degree to which native E protein sequences are not optimized for
thermodynamic stability or dimer formation and suggest that a similar structure-based approach could be used to stabilize E proteins
from other DENV serotypes and other flaviviruses. We anticipate that
many of the stabilizing mutations that we have identified will also
stabilize the E protein dimer from other DENV serotypes and Zika
virus as the mutation sites are highly conserved (fig. S9).
One notable aspect of our results is the finding that mutations in
a variety of regions within the E protein can stabilize the monomer
and/or dimer. Interchain interactions in the E dimer are concentrated in two regions, the central B dimer interface and the DII/
DIII cross-chain interface. We show that mutations at either region
can lead to a large increase in dimer affinity. IntFc2 lowers the Kd
for dimerization more than 500-fold and is located on the underside
of the central B dimer interface. IntFc8 introduces a single mutation in the FL at the DII/DIII interface and lowers the Kd 59-fold
(table S1). One likely reason why mutations similar to these are not
observed in WT DENV sequences is that they would destabilize the
energetic balance between the dimeric and trimeric postfusion conformations of the E protein and impair membrane fusion. In
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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support of this hypothesis, the crystal structure of SC.10, which
contains IntFc2 and IntFc8, adopts a dimer configuration even at
low pH (Fig. 5A). UndPk6 is interesting because it lowers the Kd for
dimerization by 54-fold, even though the mutations are in the DI/
DII hinge and do not make interactions at the dimer interface (Fig. 5A
and table S1). As the DII/DIII hinge is inherently flexible (9, 35), it
is likely that the UndPk6 mutations, especially T280P, are stabilizing the hinge in a conformation compatible with dimer formation
and are lowering the entropic cost for forming the dimer. To examine
these mutations further, we modeled the UndPk6 mutations (F279W
and T280P) onto the structure of DENV2 sE in the postfusion trimer
conformation, and the mutations are predicted to be destabilizing
for the trimer. In the postfusion conformation, the phi/psi angles
for residue 280 are −94°/101°, which is not within the allowed
region of the Ramachandran plot for proline. Our studies also
reveal that the low overall thermostability of the WT DENV2 sE
monomer is, in large part, due to the low stability of DI. The
PM4 mutation set, which contains three mutations within DI,
raises the Tm for protein unfolding from 51.0° to 62.4°C but has
little effect on the monomer-dimer equilibrium (Fig. 3B and
table S1).
All the mutation sets that markedly raised monomer or dimer
stability also increased the yield of recombinant sE. Different mechanisms may explain the increase in yield. From circular dichroism
temperature melts with the WT protein, it is evident that sE rapidly
aggregates when unfolded (24). Mutations that stabilize DI, i.e., PM4,
may reduce transient unfolding events and also promote more
11 of 18
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past. Given the overall structural similarity of flavivirus virions and
E proteins, our results will also guide the development of subunit
vaccines to other emerging pathogenic flaviviruses of humans such
as Zika, West Nile, and Yellow Fever viruses.
MATERIALS AND METHODS

Cell lines and viruses
EXPI293F (Thermo Fisher Scientific, catalog A14527) cells were
maintained in EXPI293 expression medium at 37°C with 8% CO2 at
250 rpm without antibiotics until passage 25 to improve batch-tobatch reproducibility. Vero-81 (CCL-81) cells were obtained from
the American Type Culture Collection. Vero cells were grown at 37°C
with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM),
5% fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin
(100 mg/ml), 1% GlutaMAX, 1% sodium bicarbonate, and 1% nonessential amino acids. The RNA genome of DENV2 strain 16681
was used for cloning of stabilizing mutations for transfection into
C6/36 for virus induction.
Rosetta computational design methods for predicting
DENV2 sE–stabilizing mutations
DENV2 sE dimer structure preparation and selection
of seed residues
We used four DENV2 sE crystal structures as input for design—
PDB 1OAN, 1OKE, 1TG8, and 4UTC (16, 35, 51)—to capture the
structural differences present in each DENV2 sE dimer crystal
structure. All glycan atoms, waters, and metal ions were removed
and not considered during simulations. For use of 4UTC and 1TG8
models containing all 394 residues, the unmodeled loops in 4UTC
in chain A (residues 189 to 187 and 192 to 195) and chain B (residues 14 to 19) were modeled by aligning the chain A to chain B,
extracting the coordinates of the chain containing the modeled loop
and adding them to the chain with the missing residues. For 1TG8,
the coordinates of residues 17 to 18 from chain A of 4UTC and
residues 222 to 232 from 1OAN were added and replaced, respectively, into 1TG8. All four structures were minimized five times using
the Rosetta FastRelax protocol with coordinates constrained to the
starting crystal structure coordinates.
Seed residues were selected manually with and without the use
of Rosetta. For the IntFc simulations, seed residues present at the
sE dimer interface, which allowed for overlapping design spheres,
were selected for complete sampling of the dimer interface. The
HCat simulation seed residues were influenced by the previous
reports highlighting the role of pH “sensing” histidine residues
present in flavivirus E involved in the low pH conformational
change of E (9, 52). We identified histidine residues present at the
dimer interface (H144, H27, and H261) that were in close proximity
to cationic residues, suggested to be transiently stable histidine-
cation clusters, HisCat, and selected these as seed residues for the
HCat simulations. The UndPk simulations were led by the hypothesis
that we could stabilize the sE dimer by stabilizing the sE monomer
conformation observed in the dimer crystal structure. We used
the RosettaHoles application to identify “underpacked” regions
that contain nonideal residue packing that produce small cavities
in the protein that cannot be satisfied by water, within the sE
monomer that contribute to protein instability (30). A subset of
residues that defined and allowed for complete sampling of these
regions were selected as seed residues for the UndPk simulations.
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efficient folding. Both of these factors would minimize aggregation during synthesis and folding. It is also known that secretion of
the sE protein and DENV from cells can be hindered if the FL on
DII embeds into the membrane of the host cell (34). During natural
secretion of DENV, the FL is sequestered from the host membrane
by its interaction with premembrane (prM) on the surface of the
immature virus. In our studies, prM is not present; however, stabilization of the dimer sequesters the FL at the DI/DIII interface and
may raise the energetic barrier for membrane association. In addition, IntFc8 introduces a new charged amino acid in the FL, which
is likely to disfavor insertion of the FL into membranes (34). In
general, we found that combining mutations from different regions
of the protein led to additive increases in production yield.
A primary purpose of designing stabilized DENV2 sE dimers
was to assess whether these stabilized dimers can elicit quaternary
epitope antibodies that target the E dimer. Our results suggest that
stabilized DENV2 sE dimers can elicit E dimer–specific antibodies
that appear to compete with monomer-specific antibodies, a phenomenon that has also been observed in sera of naturally infected individuals. Monomer-specific FL (FLE) antibodies and dimer-specific
2D22 and EDE antibodies have partially overlapping epitope regions on the DENV E protein and can thereby compete for binding.
Furthermore, it has been shown that the dimer-specific antibodies
have a higher affinity to DENV compared to monomer-specific FL
antibodies (15). This is consistent with our observation that depleting
serum of monomer-specific antibodies following immunization with
a stabilized dimer leaves a population of antibodies that display increased binding to DENV2 (Fig. 7, B and C).
While the FL dimer interface regions contains the most well-
characterized DENV2 type-specific quaternary antibody epitopes
(such as 2D22), DENV-specific quaternary epitope antibodies that
target epitopes at the B helix central dimer interface, near the IntFc2
mutations, have also been isolated (45, 47). Isolation and epitope
mapping of the quaternary epitope antibodies elicited by SC.14 and
SC.10 would be insightful to identify if stabilizing the central dimer
interface with IntFc2 helps to focus the elicitation of antibodies to
this region.
Our first set of immunization experiments were designed to specifically answer the question of whether the DENV2 sE monomers
(Mnmer2 and WT) or the DENV2 sE dimer (SC.14 and SC.10) antigen conformations affect the epitope focus of antibody responses,
rather than assessing the vaccinogenic potential of the novel E subunits.
We intentionally performed the immunizations without adjuvant,
which is known to affect the stability and epitope presentation of
protein antigens (46, 48–50). To assess whether the stabilized dimers
(SC.10 and SC.14) also induced DENV2-neutralizing antibodies,
we repeated the immunogenicity studies after formulating antigens
with Alhydrogel as an adjuvant. Mice immunized with the SC.10 and
SC.14 dimer variants developed higher levels of DENV2-neutralizing
antibodies than mice immunized with the WT sE antigen.
Further studies are needed to define how the binding specificity
and Fc effector properties of antibodies induced by different antigens are related to functional DENV neutralization and long-term
protection in vivo. Large-scale production of recombinant flavivirus E antigens that retain native structure is challenging because the
proteins, which must be produced in eukaryotic cells, are secreted at
low levels. The DENV2-stable dimers, which were highly thermostable and secreted from cells at much higher levels compared to
WT sE, overcome these practical limitations of antigens used in the
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In addition to the PM_ssm, we used multiple sequence alignment (MSA) from representative DENV2 strains to identify residue
positions that varied in amino acid identity in the alignment, similar
to (53), to identify additional stabilizing point mutations. We then
took the output of the mutations identified in the PM_ssm simulations, and the MSA analysis used those predicted mutations as
input for combining point mutation (PM_comb) simulations. The
seed residue positions for the PM_comb simulations were based
on the mutated positions identified in the MSA analysis, named
“atMSA” positions, and all other positions identified from the PM_ssm
simulations were named “notatMSA”. The PM_comb SHP simulations used different seed residue logic as these positions were manually
selected surface hydrophobic positions, and the simulations were
restricted to only the polar mutations from the PM_ssm at those
positions. We ran simulations where only mutations that were found
from the MSA analysis were allowed, but manual inspection eliminated further consideration of these mutations. We then focused on the
mutations obtained from PM_ssm, either atMSA or notatMSA. These
PM_comb simulations used the selection logic from the PM_ssm
simulations, but we allowed to simultaneously mutate multiple
positions in the entire domain, domain-domain interfaces, or
dimer interface. For the domain simulations, all residues in the
domain had constrained backbone sampling (±2-Å deviation)
and side chain sampling. For the interdomain and dimer interfaces, residues within a sphere of 10 Å around the combined
mutated positions had constrained backbone conformation (±2-Å
deviation) and side chain sampling. The same WT score artificial
increase used in cluster_mut was applied to all PM_Comb
simulations. The SHP simulations were divided by domain but followed
the interdomain/dimer interface selection and sampling logic. Ten
models were generated for each PM_comb and SHP simulation,
and ∆REU was calculated as indicated in the PM_ssm description.
DENV2 sE protein construct design, cloning and plasmid
preparation for cell surface display, and soluble expression
DNA encoding the DENV2 (strain 16681) sE protein (residues 1 to
394), lacking the stem and transmembrane domains, were cloned
into the modified pH mammalian expression vector, originally
derived from the pHLSec vector (54) by substitution of an alternative
multiple cloning site, containing a CAG promoter and human serum albumin signal peptide, replacing the original protein tyrosine
phosphatase  (PTP) signal sequence. DENV2 sE was expressed
for both mammalian cell surface display and soluble expression using the same pΗ vector backbone, and plasmids were renamed to
differentiate function. For mammalian surface display, sE genes
were cloned into the pD2sE_Dsp display vector, which genetically
fuses a glycine-serine (GS) GS3x-cMyc-GS3.5x linker and the MHC
I transmembrane/cytoplasmic domains to the C terminus of sE, for
membrane anchoring, following a modified system, previously reported (32), where we added a cMyc epitope tag for independent detection of sE surface display. For soluble expression, sE genes were
cloned into the pD2sE_EV8 expression vector containing a C-
terminal GS6x-His8x tag for immobilized metal affinity chromatography
purification. All DENV2 sE Rosetta variant and SC variant cloning were performed by Twist Bioscience. DENV2 sE cloned plasmids were heat-shock transformed into Escherichia coli DH5
cells for amplification, miniprepped or midiprepped using DNA
endotoxin-free kits, and stored in endotoxin-free H2O at −20°C
(Macherey-Nagel).
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IntFc, HCat, and UndPk local cluster mutation (cluster_mut)
design simulations
We used two computational design strategies to identify DENV2
sE–stabilizing mutations. The first strategy focused on designing
residues that locally cluster within 10 Å (cluster_mut) of each other
with a selected “seed residue” that defined the center of the cluster.
Within this 10-Å cluster, we created a “design sphere” that selected
all residues present within 7 Å of, and including, the seed residue
and designated these residues as “designable,” allowing Rosetta to
mutate these residues together to any of the canonical 20 amino
acids, except cysteine. We also created a “repacking sphere” that
selected residues 3 Å outside the design sphere, which do not change
the amino acid identity but allow for new side chain conformations
(or rotamers) and backbone sampling to relieve clashes from the new
mutations in the design sphere. This simulation favors multiple
mutations to promote introduction of new interactions that may
not be attainable with a single mutation to native neighboring residues. The designed sequences for each chain were forced to be identical to ensure that the final design model was a sequence-symmetric
homodimer, but the backbone movements in either chain are not
forced to be symmetric, accounting for the asymmetry observed in
the crystallographic dimers. To prevent large backbone changes, the
simulation was designed to deviate minimally (± 2-Å deviation)
from the backbone conformation observed in the crystal structure
and to reduce noise in the simulations; all residues outside the 10-Å
cluster were not sampled and remained fixed. During the simulations, we applied an artificial increase in the WT amino acid Rosetta
score (using FavorNativeBonus values of 0.0, 0.75, and 1.5), at a
given residue position, which applies stringency during the simulation and increases the probability of the Rosetta score function
accepting favorable mutation sets while restricting the number of
mutations per simulation to a reasonable number of mutations
(~1 to 5). One hundred models were created for each run, and
the scores were compared to the average top three nonmutated
model control run Rosetta total scores, where the protocol was
performed on the same selected residues, but the amino acid sequence was not changed to obtain the ∆REU score (analogous
to ∆∆Gmut).
Point mutations in silico site-saturation mutagenesis (PM_ssm),
combination (PM_comb), and SHP simulations
The second strategy is the point mutation site-saturation mutagenesis protocol (PM_ssm) that starts at the first position of the protein, and Rosetta mutates the WT amino acid to each of the 20
amino acids in independent simulations. This is repeated in both
chains simultaneously until Rosetta walks through the entire primary sequence. During the simulation, the residue position to mutate and the residues before (i − 1) and after (i + 1) in primary
sequence are selected. At the mutated position, the backbone can
move with no constraints, while the two neighboring residues can
sample side chain conformations and backbone conformations
±2 Å from the starting coordinates. All residues within 10 Å of the
mutated residue and its neighbors are allowed to sample side
chain conformations and backbone conformations with backbone constraints (±2-Å deviation). A total of 10 models were
generated for each point mutant simulation, and the total Rosetta
score for mutating to the WT amino acid was used as reference to
calculate the ∆REU score (∆∆G mut) with an arbitrary cutoff
∆REU = −2 per monomer per mutation, indicating predicted stabilizing mutations.

SCIENCE ADVANCES | RESEARCH ARTICLE

Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084

15 October 2021

Epitope presentation screen of DENV2 sE Rosetta variants
using mammalian surface display
Mammalian display vectors containing Rosetta DENV2 sE variant
genes were transiently transfected 1 g of plasmid into 1 ml of
EXPI293F cell culture using the manufacturer’s protocols for 18 hours
at 37°C in 8% CO2 in a 2-ml 96-well deep well plate (Axygen,
#P-2ML-SQ-C-S) shaking at 1000 rpm using an Orbishaker MP
3-mm orbital plate shaker. After transfection, 5 l of enhancer 1 and
50 l of enhancer 2 were added to each transfected culture and incubated for an additional 24 hours. After 42 hours after transfection
(24 hours after enhancement), cell densities were measured using a
LUNA-II cell counter (Logos Biosystems) by mixing 1:1 volume of
cell culture to trypan blue stain from six randomly selected wells on
the plate to calculate the average cell density and normalize the cell
amount for immunostaining. Cells were harvested by centrifugation
at 1000 rcf for 3 min at RT and washed one time with 800 l of RT
flow buffer, 1× PBS (pH 7.4), 1 mM EDTA, and 2% heat-inactivated
FBS. After washing, the cells were resuspended with RT flow buffer
to a final density of 5.0 × 106 cells/ml, and 1.5 × 106 cells were transferred to a 1-ml 96-well deep well plate (Eppendorf, #951032603).
Cells were then labeled with 100 l of chicken anti-cMyc immunoglobulin Y (IgY) fraction polyclonal antibody (10 g/ml) at RT for
10 min at 1000 rpm using an Eppendorf ThermoMixer C with
SmartBlock DWP1000 adapter. Cells were centrifuged at 1000 rcf
for 3 min at RT and washed two times with RT flow buffer (one time
with 500 l and one time with 600 l). All wash steps followed this
protocol except where noted. Cells were then labeled with 100 l of
anti-chicken antibody (2 g/ml), labeled with Alexa Fluor 488, at
RT for 15 min at 1000 rpm. Cells were washed two times with RT
flow buffer and labeled with 100 l of DENV anti-E antibody (3H5,
1C19, EDE1 C8, EDE1 C10, or 2D22) (1 g/ml) for 1 hour at either
RT or 40°C at 1000 rpm using ThermoMixer C and deep well adaptors to ensure homogenous mixing and heating. Cells were then
centrifuged at the same temperature used for labeling and washed
two times (one time with 600 l and one time with 700 l) with either RT flow buffer for RT stained cells or pre-equilibrated 40°C
flow buffer for 40°C stained cells. Cells were then left at RT for
15 min to allow for equilibration to RT and stained with 100 l of
anti-human IgG PerCP (5 g/ml) or anti-mouse IgG PerCP (2 g/ml)
for 10 min at RT. Cells were washed two times with RT flow buffer
and resuspended in 500 l of flow buffer for analysis. Cells were
analyzed using a Millipore Sigma Guava 5HT flow cytometer with
excitation of both Alexa Fluor 488 and PerCP with 488-nm laser and
gating on the Alexa Fluor 488–positive fluorescence in the green
fluorescence channel (525/30), and 20,000 events were collected in
the red fluorescence channel (695/50). Cells transfected with only
the GS linkers, cMyc, and MHC I anchor (MHC ctrl) and stained
with anti-cMyc, 3H5, anti-chicken Alexa Fluor 488 was used as fluorescence minus one (FMOgreen) controls to set the green fluorescence channel voltages baseline, and the same cells stained with
anti-cMyc, 3H5, and anti-mouse PerCP were used to set red fluorescence channel baseline (FMOred). FMOgreen controls were also
used for compensation of the red fluorescence channel to eliminate
Alexa Fluor 488 fluorescence spillover. Files were converted to .fcs
format using Guava InCyte software and gating and using MHC
ctrl–stained cells, and geometric mean fluorescence intensities
(GMFIs) were performed and obtained using FlowJo and Microsoft
Excel. Fluorescence ratio was calculated by dividing the PerCP
GMFI of the sE variant–displayed cells stained with anti-E antibody
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Small- and large-scale DENV2 sE protein expression
and purification
Small-scale expression and purification of DENV2 sE variants
EXPI293F cells were transiently transfected according to the manufacturer’s protocol with a modified cell density of 3.0 × 106 cells/ml
and 75% of the total final volume (i.e., 90 ml for 120 ml of final
culture), with 1 g of DENV2 sE protein containing plasmid per
milliliter of cell culture, for 18 hours at 37°C with 8% CO2 at 250 rpm.
Following transfection, enhancers 1 (600 l at 120-ml scale) and 2
(6 ml at 120-ml scale) and 12 ml of 3.5% of Hyclone Cell Boost 1
(GE Healthcare) were added to the cells to increase protein expression and reduce cell death. Cell culture supernatant was harvested
after 24 hours by pelleting cells at 1000 relative centrifugal force
(rcf) at room temperature (RT) for 10 min and further clarified
using a 0.22-m vacuum filter (Millipore). DENV2 sE His-tagged
proteins were affinity purified by batch-binding clarified medium
with pre-equilibrated penta-Ni resin (Marvelgent) for 1 hour at 4°C
and then transferred into a column to collect the resin. A two-step
wash was performed by gravity at RT (~23°C) to eliminate protein
contaminants. The first wash was performed three times with 5 CV
(column volume) of high-salt tris buffer [50 mM tris (pH 8.0) and
1 M sodium chloride with 25 mM imidazole], and the second was
performed with 1 CV wash with 1× PBS (pH 7.4) with 50 mM imidazole. Bound proteins were eluted in one step using 5 CV (two times
with 400 l and two times with 600 l) of 1× PBS (pH 7.4) and 500 mM
imidazole to collect the protein and then sequential concentration
at 4°C using a 10K MWCO Amicon-4 followed by an Amicon-0.5
centrifugal filter at maximum allowed rcf for each filter. The concentrated elution was buffer exchanged using a 1Å~ PBS (pH 7.4)
pre-equilibrated 7K 0.5-ml MWCO ZebaSpin desalting column
(Thermo Fisher Scientific). Purity was assessed by SDS–polyacrylamide
gel electrophoresis (SDS-PAGE), by loading 3.5mg. Concentrations
were measured and calculated by measuring the absorbance at 280 nm
and using the ProtParam-derived theoretical extinction coefficient.
Yields are reported as yield after purification in milligrams of
protein per liter of culture.
Large-scale production for crystallography and
immunogenicity studies
Mammalian expression vectors encoding for soluble DENV2 sE
proteins were transfected into EXPI293F cells, as per the manufacturer’s protocols (Thermo Fisher Scientific), and culture supernatants
were harvested on day 4 after transfection. Supernatants were then
buffer exchanged by tangential flow filtration into TALON binding
buffer [50 mM sodium phosphate (pH 7.4), 500 mM NaCl, 5 mM
imidazole, 0.02% sodium azide, and 10% glycerol] and then run
through hand-packed TALON columns with flow adapters, recirculating overnight at 4°C. The next day, columns were switched to
flow through, and after complete loading, columns were washed
with 10 CV of binding buffer, followed by 10 CV of binding buffer
with 10 mM imidazole. Bound proteins were eluted with 10 CV of
elution buffer (binding buffer with 150 mM imidazole). Wash and
elution fractions were analyzed by SDS-PAGE, and DENV2
protein–containing fractions were pooled and concentrated before further purification by SEC on Superdex 200 16/600 into PBS
with 10% glycerol. Fractions containing DENV2 proteins were then
pooled, concentrated, aliquoted, and flash-frozen in liquid nitrogen
and stored at −80°C. Endotoxin levels were measured at 1:20 dilution in endotoxin-free water with a nexgen-PTS reader (Charles
River Laboratories).
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by the GMFI of the WT sE-transfected cells stained with the same
antibody. Anti-DENV antibody stained cells with <1000 events and
had no observable signal upon manual review were considered negative, and the PerCP-negative GMFI (Q4) was used for Fr calculations.

SEC-MALS to validate DENV2 sE variant dimer stability
Proteins were centrifuged at 14,000 rcf for 10 to 12 min at 4°C to
remove any debris or aggregates, and concentrations were obtained
by measuring the absorbance at 280 nm and using theoretical molar
extinction coefficients with monomer molecular weights before
analysis. Ice-cold DENV2 sE proteins at 2.5 mg/ml (250 g), with
exception for DENV2 sE Mnmer2 (1.5 mg/ml, 150 g) and DENV2
sE IntFc2 (1.6 mg/ml, 160 g), were loaded at a flow rate of 0.5 ml
min−1 with 1× PBS (pH 7.4) + 200 mM sodium azide onto a GE
Superdex 200 10/300 GL column–equipped Agilent FPLC system,
interfaced with a Wyatt DAWN HELEOS II light scattering instrument, Wyatt T-rEX refractometer, and a Wyatt dynamic light scattering module. All buffers and equipments were maintained at
either RT (~23°C) or 37°C for the entire experiment. For 37°C
experiments, buffers were placed in a temperature-controlled water
bath, and all WYATT equipments were set to 37°C. The column
was wrapped in 12-inch, THG Thermal Tape (Reptile Basics Inc.)
and regulated by a digital thermostat (RINGDER RC-112R) set at 37°C
with 0.01°C difference (diff = 0.01)s and 5-second delay (delay = 005).
The entire system was equilibrated for ~2 hours before protein
analysis to ensure equilibration, and WAYTT systems reached
baseline signal. MALS data were collected and analyzed using Wyatt
ASTRA (version 6) software.
Crystal structure of DENV2 sE SC.10
SC.10 was concentrated to 3.3 mg/ml, aliquoted, and stored at
−80°C in 1× PBS (pH 7.4) + 10% glycerol. Before laying drops, the
protein was quickly hand-thawed and buffer exchanged into 25 mM
tris (pH 7.4) with 0.1 M sodium chloride using a Thermo Fisher
Scientific Zeba 7K MWCO desalting column. Crystallization screening
was performed by sitting drop vapor diffusion method by mixing
100 nl of SC.10 and with 100 nl of precipitant solution using a SPT
Labtech mosquito LV robot. Diffraction quality crystals of SC.10
were grown by mixing 200 nl of protein solution with 200 nl of precipitant solution containing 15% polyethylene glycol 3350 (pH 4.4),
0.1 M sodium acetate, and 0.1 M sodium iodide. SC.10 crystals were
formed after 3 days at 21°C. The crystals were cryo-protected with
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Direct ELISA to measure monoclonal antibody binding
to DENV2 sE variants
Ni2+-coated ELISA plates (Thermo Fisher Scientific, PI15142) were
used to capture 45 nM sE protein in 1× tris-buffered saline (TBS)
[50 mM tris-Cl (pH 7.5) and 150 mM NaCl] for 1 hour at 37°C. The
plate was washed three times with 1× TBS + 0.2% Tween 20 (wash
buffer). Next, the plate was blocked using 1× TBS + 3% skim milk +
0.05% Tween 20 (blocking buffer) for 1 hour at 37°C and subsequently
washed three times with wash buffer. The plate was then incubated
for 1 hour at 37°C with 2 ng/l of CR or TS human monoclonal
antibody—1M7 (Flavi CR), 1C19 (DENV CR), 3F9 (DV2 TS), 2D22
(DV2 TS), EDE1 C8 (DENV/ZIKV CR), and EDE2 A11 (DENV
CR)—or mouse monoclonal antibody—3H5 (DV2 TS) and 4G2
(CR)—in blocking buffer and washed three times with wash buffer.
The wells were accordingly treated with either alkaline phosphatase
(AP)–conjugated anti-mouse IgG (1:1000; Sigma-Aldrich) or AP-
conjugated anti-human IgG (1:2500; Sigma-Aldrich) for 45 min at
37°C. Last, the plate was washed and developed with AP substrate
(Sigma-Aldrich), and the absorbance was measured at 405 nm.
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Assessment of DENV2 sE variant dimer and monomer
protein stability using nanoDSF
sE proteins were stored in 1× PBS (pH 7.4) and diluted to 2, 4, or
8 M into the same buffer and maintained on ice before analysis.
Thermal melts were performed using a NanoTemper Prometheus
NT.48, in duplicate, by transferring 10 l of diluted protein into a
capillary and monitoring fluorescence at 330 or 350 nm, as designated,
with a ramping rate of 1°C min−1 from 15° to 95°C. Melting transition points (Tm) were calculated using Nanotemper PR.ThermControl
software. For van’t Hoff analysis, thermal melts were performed at
concentrations ranging from 2 to 16 M with same settings as single
concentration measurements. The concentration tested and the
measured Tm1 were used for 1/T and ln(Kd) values, respectively, as
previously determined (24). Ninety-five percent confidence limits
for the homodimer Kds at 37°C were obtained using error propagation and the linear regression fits used for van’t Hoff analysis.

the mother liquor containing 25% glycerol. The crystals diffracted
to a final resolution of 3.42 Å. The diffraction data were processed
and scaled using XDS (55) and Aimless (56). The phases were obtained by MR with Phaser (57) by using chain A of PDB: 1OAN, the
structural model used for the design of IntFc2, IntFc8, and UndPk6.
The MR failed when using the entire 1OAN chain A but was successful when using two separated models (DI/DII and DIII) generated
from 1OAN chain A. The final model was built using Coot (58, 59)
and iterative refinement with Phenix (60) to a Rfree/Rwork of 33.7/31.8,
with the asymmetric unit containing a single sE monomer. Among
structures of similar resolution, PDB 6WY1 (SC.10) has the lowest
MolProbity clashscore (61) and has a model quality consistent with
a resolution of 2.4 Å. Electron density for all mutations was observed,
with the strongest density observed for G106D, F279W, T280P, and
A259W, including the first N-acetylglucosamine moiety of N67.
Residues 148 to 158 consisting of the DI glycan loop residues were
not modeled because of insufficient density. A strong positive density is observed in the map near residue 144 that was not modeled in
the PDB-deposited model; however, the N-terminal methionine
conformation present in the previously reported DENV2 sE dimer
crystal structures matches the position of the unmodeled positive
density present in our map. An alternative model, modeled with the
N-terminal methionine matching the 1OAN N terminus, satisfies
this positive density but leaves an even stronger positive density near
the FL unsatisfied (fig. S3C). Modeling alternative conformations for
residues 1 to 3 in both conformations does not satisfy either density.
The deviation of the N terminus in our structure is consistent with the
N-terminal conformational change observed in the low pH structure
of DENV2 sE complexed with prM (PDB 3C5X) and also observed
in nearby regions in our structure such as near the ij loop and
FL. Chain D in the PDB 4UT9 EDE1 C10 antibody–bound sE structure also contains a N-terminal conformation that deviates from
the canonical DENV2 sE N-terminal conformation, giving further
evidence to the potential for multiple N-terminal conformations
(16). The density near the FL is also weaker in comparison to the rest
of the structure, suggesting that this region is likely affected by low
pH-induced mobility. The deviation of the FL W101 conformation
has also been observed in a ZIKV sE crystal structure complexed
with an antibody bound to DI/DIII (PDB 6NIU, chain A) (62).
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Mouse immunogenicity studies
Immunogenicity studies at the University of North Carolina
Mouse experiments were performed under protocols approved by
the Institutional Animal Care and Use Committee of the University
of North Carolina. All experiments followed ethical and federal regulations according to the Public Health Service Policy on Humane
Care and Use of Laboratory Animals, Animal Welfare Act, and the
Guide for the Care and Use of Laboratory Animals. In the first
immunogenicity study performed without adjuvant, 6-week-old female
Balb/c mice (Jackson Laboratory) were immunized subcutaneously
with DENV2 rE Mnmer2 (n = 5), rE WT (n = 5), rE SC.14 (n = 5),
rE SC.10 (n = 5) antigens, or vehicle (isotonic 9.25% sucrose/H2O)
alone (n = 3). All groups were primed and boosted at weeks 3 and 8
(5 g of antigen per dose per mouse), and serum samples were collected at week 16 by submandibular bleed to characterize DENV2-
specific antibodies. In the second study performed with Alhydrogel
as an adjuvant, 6-week-old female C75BL/6J mice (Jackson Laboratory)
were immunized subcutaneously with 10 g of rE WT (n = 5), rE
SC.14 (n = 5), or vehicle (isotonic 9.25% sucrose/H2O) alone (n = 4)
formulated with Alhydrogel (Invitrogen) as an adjuvant (250 g per
dose). All groups were primed and boosted at week 3, and serum
samples were collected at week 9 by submandibular bleed to characterize DENV2-specific antibodies.
Immunogenicity studies at the Walter Reed Army Institute
for Research
Research was conducted under an animal use protocol approved by
the Walter Reed Army Institute for Research/Naval Medical Research Center Institutional Animal Care and Use Committee in an
AAALAC (American Association for Accreditation of Laboratory
Animal Care) International–accredited facility, in compliance with
the Animal Welfare Act and other federal statutes and regulations
Kudlacek et al., Sci. Adv. 2021; 7 : eabg4084
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relating to animals and experiments involving animals, and adheres
to principles stated in the Guide for the Care and Use of Laboratory
Animals, NRC Publication, 2011 edition. Groups of six 8-week-old
female C57BL/6J mice (Jackson Laboratory) were subcutaneously
immunized with DENV2 rE WT, rE Mnmer2, or rE SC.10 antigens
(5 g of antigen per dose per mouse) with or without Alhydrogel
(Invitrogen) (500 g of adjuvant per dose). All groups were primed
and boosted at week 3, and blood samples were collected at week 8
by submandibular bleed to characterize DENV2-binding and
DENV2-neutralizing antibodies.
Depletion of variant E antigen-specific antibodies from mouse
immune sera
DENV2 sE Mnmer2 or SC.14 (35.2 g) at 75 g/ml in equilibration
buffer [50 mM HNa2O4P (pH 8), 0.3 M NaCl, and 10 mM imidazole]
was loaded into 880 g of Ni-NTA magnetic beads (HisPur, Thermo
Fisher Scientific, #88832), in a 1.7-ml Eppendorf tube, at a 4-g antigen to 100-g bead ratio, and incubated at 37°C for 30 min, mixing
1000 rpm using a ThermoMixer C. Antigen-loaded beads were washed
two times with 400 l of equilibration buffer. Serum diluted (1:50)
was depleted by incubating 440 g of antigen-loaded beads for 1 hour
at 37°C while mixing at 1000 rpm, then briefly centrifuged for 30 s
at 2400 rcf at 37°C and placed onto a magnetic strip to collect beads,
and repeated for one to two more rounds of depletion. Sera depletion was considered complete when, compared to undepleted sera,
ELISA analysis of depleted sera at 1:100 against the homologous
depletion antigen resulted in reduction of signal to background levels.
Depleted sera were stored at 4°C until further analysis.
Characterization of depleted mouse immune sera by ELISA. Undepleted and depleted mouse sera were characterized by antigen-
capture ELISA. To evaluate post-depletion binding to DENV2
virus, 96-well ELISA plates (Greiner, #655061) were coated with
1M7 (2 g/ml) in 0.1 M bicarbonate buffer (pH 9.6) overnight (~18
hours) at 4°C and then washed three times with wash buffer. Next,
the plates were blocked with blocking buffer for 1 hour at 37°C. After washing, DENV2 in culture supernatant was diluted 1:10 in
blocking buffer and added to each well and incubated for 1 hour at
37°C for capture by 1M7. To determine post-depletion binding to
Mnmer2 (M2) or SC.14 antigens, Ni2+-coated ELISA plates (Pierce)
were incubated with 50 l of Mnmer2 or SC.14 protein, at 2 g/ml,
for 1 hour at 37°C and were blocked with blocking buffer for 1 hour
at 37°C and washed three times with washing buffer. Following
blocking, the DENV2 capture and Mnmer2/SC.14 direct ELISAs all
followed the same protocol. Undepleted or depleted mouse serum
was serially diluted in blocking buffer and incubated for 1 hour at
37°C. After incubation, the plates were washed in wash buffer and
incubated with AP-conjugated anti-mouse IgG (1:1000 dilution;
Sigma-Aldrich) for 45 min at 37°C. Next, the plates were washed
and developed with the AP substrate (Sigma-Aldrich), and the absorbance was measured at 405 nm. End point dilution (EPD) is determined by the dilution where detection levels reach background
levels obtained from data fitting using a linear regression curve with
a sigmoidal slope, calculated by the GraphPad Prism software.
DENV2 neutralization assay
Ninety-six-well flat-bottom plates were coated with 2 × 104 Vero-81
cells per well and incubated at 37°C overnight. Neutralization titers
were determined by threefold serial dilutions of sera mixed with
30 to 40 focus-forming units per well of DENV2 in DMEM/F12
supplemented with 2% FBS. The sera-virus mixtures were incubated
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Binding analysis between DENV2 sE variants and anti-E
antibodies using BLI
BLI experiments were carried out using the ForteBio Octet Red384
system with DENV2 sE proteins immobilized on Ni-NTA biosensors
(Satorius, #18-5101) and antibodies as analytes. All protein solutions used for BLI experiments were prepared in 1× kinetics buffer
(Satorius, #18-1105) at RT. Ten nanomolar sE proteins (WT, Cm1,
Mnmer2, SC.10, and SC.14) were used for loading. Antibody samples were prepared by twofold serial dilutions with monomer epitope antibodies (4G2 and 3H5) concentrations ranging from 50 to
3.125 nM and quaternary epitope antibodies (2D22, EDE1 C8, and
EDE1 C10) from 50 to 6.25 nM. Measurements in the absence of
analyte were used as reference for data subtraction. Kinetics buffer
(1×) was used to equilibrate the sensors before loading of sE. Each
solution (250 l) was added to a sample tray (Greiner, #655209). To
start the experiment, Ni-NTA biosensors were soaked in water at
RT for 15 min, while the sample tray was incubated at 37°C. All the
following steps were performed at 37°C. The sensors were then
equilibrated for 15 min, loaded with sE proteins for 5 min, and
washed for 2 min in 1× kinetics buffer. The immobilized proteins
were incubated with antibody solutions for 15 min (association) and
then in buffer for 25 min (dissociation). BLI sensorgrams were analyzed using the ForteBio Data Analysis 11.0 software. Sensorgrams
were subtracted by the reference data and processed after aligning
the y axis by baseline and correcting the interstep by aligning to
dissociation. Steady-state binding constants were calculated using
the maximum response (Rmax) for each antibody concentration.

SCIENCE ADVANCES | RESEARCH ARTICLE
at 37°C for 1 hour before transferring to the 96-well plates containing confluent Vero-81 monolayers. Following an additional 1 hour
of incubation at 37°C, the medium on the monolayers was replaced
by Opti-MEM (Gibco, Thermo Fisher Scientific) containing 2% FBS
and 1% (w/v) carboxymethyl cellulose (Sigma-Aldrich). Infected cells
were left to incubate for 44 hours at 37°C with 5% CO2. Next, cells
were washed with 1× PBS and fixed with 4% paraformaldehyde.
Fixed cells were permeabilized and followed by blocking with 5%
nonfat dried milk in permeabilization buffer. The cells were then
incubated with a mix of 4G2 and 2H2 primary antibodies for 1 hour
at 37°C, washed, followed by secondary horseradish peroxidase–
conjugated anti-mouse IgG [Kirkegaard & Perry Laboratories
(KPL) antibodies, LGC Clinical Diagnostics, Inc.] for 1 hour at
37°C, washed again, and developed with TrueBlue peroxidase substrate (KPL). The reaction was stopped with water, and the plates
were air-dried before counting the foci on an ImmunoSpot S6 analyzer
(Cellular Technology Limited) using the ImmunoSpot double-count
software. We calculated 50% focus reduction neutralization test
(FRNT50) values using the sigmoidal dose response (variable slope)
equation in GraphPad Prism software.

View/request a protocol for this paper from Bio-protocol.
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